Tuesday 18 February 2014

The US FDA has issued full approval for Israeli drugmaker Teva’s Synribo (omacetaxine mepesuccinate)高三尖杉酯碱 for chronic myeloid leukaemia (CML). « New Drug Approvals

No comments:

Post a Comment